Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.
Pathol Res Pract. 2021 Mar;219:153348. doi: 10.1016/j.prp.2021.153348. Epub 2021 Jan 27.
Despite the rapid development of novel adjuvant and neoadjuvant chemotherapeutic drugs in recent years, advanced ovarian cancer still lacks effective treatment strategies and remains one of the main causes of death among women. Wnt protein family is widely expressed in a variety of human tissues, and Wnt5a is an important member of the noncanonical Wnt pathway. Wnt5a has been found to induce tumor suppression as well as to function as an oncogene depending upon the specific cancer type. In ovarian cancer, Wnt5a protein expression has been observed to be significantly upregulated and associated with poor prognosis. Researchers found that downregulating Wnt5a expression levels effectively suppresses ovarian cancer cell migration and invasion abilities. We believe that the downregulation of Wnt5a will be an attractive and promising antimetastatic therapeutic approach for the future treatment of patients with advanced ovarian cancer. The present review focuses on the mechanisms and therapeutic potential of Wnt5a as a promising novel therapeutic target for ovarian cancer.
尽管近年来新型佐剂和新辅助化疗药物发展迅速，但晚期卵巢癌仍缺乏有效治疗策略，仍是女性死亡的主要原因之一。Wnt 蛋白家族广泛表达于多种人体组织中，Wnt5a 是非经典 Wnt 通路的重要成员。Wnt5a 已被发现可根据特定癌症类型诱导肿瘤抑制或作为癌基因发挥作用。在卵巢癌中，Wnt5a 蛋白表达水平显著上调，并与不良预后相关。研究人员发现，下调 Wnt5a 表达水平可有效抑制卵巢癌细胞的迁移和侵袭能力。我们认为下调 Wnt5a 将成为未来治疗晚期卵巢癌患者有吸引力和有前途的抗转移治疗方法。本综述重点介绍了 Wnt5a 的作用机制和治疗潜力，将其作为一种有前途的新型卵巢癌治疗靶点。
